Cellectis (NASDAQ:CLLS) Rating Increased to Buy at Zacks Investment Research

Zacks Investment Research upgraded shares of Cellectis (NASDAQ:CLLS) from a hold rating to a buy rating in a research note published on Thursday, Zacks.com reports. The firm currently has $17.00 price objective on the biotechnology company’s stock.

According to Zacks, “Cellectis SA is a gene-editing company. The company focused on developing immunotherapies based on gene edited engineered CAR-T cells. Cellectis SA is based in Paris, France. “

Other equities research analysts also recently issued reports about the company. ValuEngine downgraded Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd. BidaskClub upgraded Zai Lab from a buy rating to a strong-buy rating in a report on Friday, June 28th. Finally, Citigroup set a $27.00 price target on PhaseBio Pharmaceuticals and gave the stock a buy rating in a report on Friday, May 24th. Two analysts have rated the stock with a sell rating, two have given a hold rating and four have assigned a buy rating to the company. The company currently has a consensus rating of Hold and a consensus target price of $31.60.



NASDAQ CLLS opened at $15.23 on Thursday. The firm has a 50-day moving average of $15.55. The company has a market capitalization of $633.65 million, a P/E ratio of -7.89 and a beta of 1.73. The company has a quick ratio of 9.74, a current ratio of 9.77 and a debt-to-equity ratio of 0.07. Cellectis has a 12 month low of $13.84 and a 12 month high of $30.62.

Cellectis (NASDAQ:CLLS) last released its quarterly earnings data on Tuesday, May 7th. The biotechnology company reported ($0.36) EPS for the quarter, beating analysts’ consensus estimates of ($0.63) by $0.27. The business had revenue of $3.43 million during the quarter, compared to the consensus estimate of $3.70 million. Cellectis had a negative return on equity of 14.85% and a negative net margin of 401.24%. On average, equities research analysts predict that Cellectis will post -2.32 EPS for the current year.

Several institutional investors have recently made changes to their positions in the business. ARK Investment Management LLC increased its holdings in shares of Cellectis by 30.8% in the first quarter. ARK Investment Management LLC now owns 934,076 shares of the biotechnology company’s stock worth $17,131,000 after acquiring an additional 219,740 shares in the last quarter. Nikko Asset Management Americas Inc. bought a new stake in shares of Cellectis in the first quarter worth about $15,084,000. Sumitomo Mitsui Trust Holdings Inc. bought a new stake in shares of Cellectis in the first quarter worth about $14,987,000. Macquarie Group Ltd. increased its holdings in shares of Cellectis by 15.0% in the fourth quarter. Macquarie Group Ltd. now owns 219,675 shares of the biotechnology company’s stock worth $3,658,000 after acquiring an additional 28,688 shares in the last quarter. Finally, New York State Common Retirement Fund bought a new stake in shares of Cellectis in the fourth quarter worth about $1,658,000. Institutional investors own 30.62% of the company’s stock.

Cellectis Company Profile

Cellectis SA, a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia (ALL); UCART22 to treat ALL and non-Hodgkin lymphoma (NHL); ALLO-501 for treating relapsed/refractory NHL; and UCART123 for the treatment of acute myeloid leukemia (AML) and blastic plasmacytoid dendritic cell neoplasm.

See Also: How to read a candlestick chart

Get a free copy of the Zacks research report on Cellectis (CLLS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Cellectis (NASDAQ:CLLS)

Receive News & Ratings for Cellectis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cellectis and related companies with MarketBeat.com's FREE daily email newsletter.